Search International and National Patent Collections

WIPO logo
1. (WO2018223832) USE OF PLASMA S100A12 IN EARLY DIAGNOSIS OF ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION

Pub. No.:    WO/2018/223832    International Application No.:    PCT/CN2018/087422
Publication Date: Fri Dec 14 00:59:59 CET 2018 International Filing Date: Sat May 19 01:59:59 CEST 2018
IPC: G01N 33/68
G01N 1/28
G01N 1/30
G01N 33/535
Applicants: THE GENERAL HOSPITAL OF SHENYANG MILITARY REGION OF THE CHINESE PEOPLE'S LIBERATION ARMY
中国人民解放军沈阳军区总医院
Inventors: HAN, Yaling
韩雅玲
ZHANG, Xiaolin
张效林
CHENG, Minghui
程茗慧
GAO, Naijing
高乃婧
YAN, Chenghui
闫承慧
TIAN, Xiaoxiang
田孝祥
LI, Yi
李毅
LIU, Dan
刘丹
Title: USE OF PLASMA S100A12 IN EARLY DIAGNOSIS OF ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION
Abstract:
The present invention falls within the technical field of medical biology, and in particular relates to the use of plasma S100A12 in very early diagnosis of ST-segment elevation myocardial infarction (STEMI). S100A12 is a member of the calcium binding protein family which is mainly secreted by myocardial cells, vascular smooth muscle cells of vascular wall atherosclerosis plaque and blood neutrophils. S100A12 is a protein having a molecular weight of 12 KD, contains two EF chiral calcium ion binding areas, and can be rapidly released into circulating blood from myocardial cells, vascular smooth muscle cells and neutrophils after acute myocardial infarction outsets due to the relatively small molecular weight thereof, and an increase in the expression level of S100A12 can be detected early on (within 30 minutes of chest pain) during the occurrence of acute myocardial infarction, and S100A12 can be used as a biomarker for the early diagnosis of STEMI.